Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

8. září 2022 aktualizováno: Amgen

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for adults with relapsed multiple myeloma. Eligible subjects will be randomized in a 1:1 ratio to receive either the control Rd or CRd. Randomization will be stratified by β2 microglobulin levels (< vs ≥ 2.5 mg/L), prior bortezomib (no vs yes), and prior lenalidomide (no vs yes). Participants will receive the treatment determined by randomization in 28-day cycles until disease progression or unacceptable toxicity (whichever occurs first).

Typ studie

Intervenční

Zápis (Aktuální)

792

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Belgie
      • Antwerpen, Belgie, 2060
        • Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg
      • Brugge, Belgie, 8000
        • AZ Sint-Jan AV
      • Brussels, Belgie, 1090
        • UZ Brussel
      • Bruxelles, Belgie, 1000
        • Institut Jules Bordet
      • Bruxelles, Belgie, 1200
        • Cliniques Universitaires Saint-Luc
      • Leuven, Belgie, 3000
        • UZ Leuven
  • Bulharsko
      • Pleven, Bulharsko, 5800
        • University Multiprofile Hospital for Active Treatment, "Dr. Georgi Stranski"
      • Plovdiv, Bulharsko, 4002
        • University Multiprofile Hospital for Active Treatment "Sveti Georgi"
      • Sofia, Bulharsko, 1606
        • Military Medical Academy Multiprofile Hospital for Active Treatment
      • Sofia, Bulharsko, 1756
        • Specialized Hospital for Active Treatment of Hematological Diseases
      • Varna, Bulharsko, 9010
        • Multiprofile Hospital for Active Treatment "Sveta Marina"
  • Francie
      • Clamart, Francie, 92140
        • Hospital Antoine Beclere
      • Le Mans, Francie, 72000
        • Clinique Victor Hugo - Centre Jean Bernard
      • Lille, Francie, 59037
        • Hôpital Claude Huriez
      • Mulhouse, Francie, 68070
        • CH de Mulhouse, Hopital Emile Muller
      • Nantes, Francie, 44093
        • CHU Nantes Hôtel Dieu
      • Paris, Francie, 75012
        • Hopital Saint-Antoine
      • Paris, Francie, 75015
        • Groupe Hospitalier Necker - Enfants Malades
      • Toulouse, Francie, 31100
        • Cancer Institut Universitaire de Toulouse-Oncopole (iUCT)
      • Vandoeuvre-Les-Nancy, Francie, 54511
        • Hopitaux de Brabois
  • Holandsko
      • Rotterdam, Holandsko, 3015 CE
        • Erasmus MC, Department of Haematology
  • Itálie
      • Milano, Itálie, 20162
        • Azienda Ospedallera Niguarda Ca Granda
      • Novara, Itálie, 28100
        • Azienda Ospedllero Maggiore della Carita
      • Pisa, Itálie, 56216
        • Azienda Ospedaliera Pisana Ospendale Santa Chiara - Main
      • Roma, Itálie, 00144
        • Ospedale S. Eugenio
      • Torino, Itálie, 10126
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino
  • Izrael
      • Haifa, Izrael, 31096
        • Rambam Medical Center
      • Jerusalem, Izrael, 91120
        • Hadassah Medical Center, Ein Kerem
      • Nahariya, Izrael, 22100
        • Western Gailee Hospital - Nahariya
      • Petach Tikva, Izrael, 49100
        • Rabin Medical Center
      • Ramat Gan, Izrael, 52621
        • The Chaim Sheba Medical Center
      • Rehovot, Izrael, 76100
        • Kaplan Medical Center
  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
        • Tom Baker Cancer Centre
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • University of Alberta, Cross Cancer Institute
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Vancouver General Hospital
    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3E 0V9
        • Cancer Care Manitoba
    • Newfoundland and Labrador
      • St John's, Newfoundland and Labrador, Kanada, A1B 3V6
        • General Hospital, Health Sciences Centre
    • Ontario
      • Toronto, Ontario, Kanada, M5G 2M9
        • Princess Margaret Hospital
    • Quebec
      • Montreal, Quebec, Kanada, H3A 1A1
        • McGill University Health Center, Royal Victoria Hospital
      • Montreal, Quebec, Kanada, H3T 1E2
        • Sir Mortimer B. Davis - Jewish General Hospital
  • Maďarsko
      • Budapest, Maďarsko, H-1097
        • St. Istvan and St. Laszlo Hospital of Budapest
      • Debrecen, Maďarsko, H-4032
        • University of Debrecen, Medical and Health Science Center
      • Gyor, Maďarsko, H-9032
        • Petz Aladár County Teaching Hospital
      • Gyula, Maďarsko, H-5700
        • Bekes County Pandy Kalman Hospital
      • Kaposvar, Maďarsko, H-7400
        • Kaposi Mór County Teaching Hospital
      • Pecs, Maďarsko, H-7624
        • University of Pecs
      • Szeged, Maďarsko, H-6720
        • University of Szeged, Albert Szent-Gyorgi Clinical Center
  • Německo
      • Dusseldorf, Německo, 40225
        • University of Dusseldorf
      • Frankfurt am Main, Německo, 60488
        • Krankenhaus Nordwest
      • Hamburg, Německo, 20246
        • University of Hamburg-Eppendorf
      • Heidelberg, Německo, 69120
        • Universitat Heidelberg
      • Koblenz, Německo, 56068
        • Stiftungsklinikum Mittelrhein
      • Munchen, Německo, 81377
        • LMU Klinikum der Universität
      • Munster, Německo, 48129
        • Universitätsklinikum Münster
      • Wurzburg, Německo, 97080
        • Universitätsklinikum Würzburg
  • Polsko
      • Gdansk, Polsko, 80-952
        • University Clinical Centre, Department of Hematologii Transplantologii
      • Gorzow Wielkopolski, Polsko, 66-400
        • Samodzielny Publ. Szp. Wojewodzki w Gorzow Wlkp.
      • Katowice, Polsko, 40-027
        • Independent Public Teaching Hospital of Medical University of Silesia in Katowice
      • Lodz, Polsko, 93-510
        • Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz
      • Suwalki, Polsko, 16-400
        • Szpital Wojewwodzki im. dr Ludwika Rydygiera w Suwalkach
      • Torun, Polsko, 87-100
        • Nicolaus Copernicus Municipal Specialist Hospital
      • Warszawa, Polsko, 02-781
        • Maria Sklodowska-Curie Institute of Oncology
      • Zamosc, Polsko, 22-400
        • Zamojski Non-Public Hospital
  • Rakousko
      • Wien, Rakousko, 1090
        • Medizinische Universitat Wien
      • Wien, Rakousko, 1171
        • Wilhelminspital der Stadt Wien, Zentrum fur Onkologie und Hamatologie
  • Rumunsko
      • Bucharest, Rumunsko, 022328
        • Fundeni Clinical Institute, "Stefan Berceanu" Center for Hematology and Bone Marrow Transplantation
      • Bucharest, Rumunsko, 030-171
        • Coltea Clinical Hospital
      • Bucharest, Rumunsko, 050098
        • Bucharest University Emergency Hospital
      • Iasi, Rumunsko, 700483
        • Regional Institute of Iasi
  • Ruská Federace
      • Izhevsk, Ruská Federace, 426039
        • First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia
      • Moscow, Ruská Federace, 115478
        • Federal State Budgetary Scientific Institution: N.N. Blokhin Russian Cancer Research Center
      • Moscow, Ruská Federace, 125101
        • Moscow State Medical Institution Municipal City Clinical Hospital n.a. S.P. Botkin
      • Moscow, Ruská Federace, 125167
        • Federal State Budget Institution: Hematology Research Center under MoH
      • St. Petersburg, Ruská Federace, 191024
        • FSBI: Russian Research Institute of Hematology and Blood Transfusion under the Ferderal Agency for M&B
      • St. Petersburg, Ruská Federace, 197022
        • State Higher Educational Institution: St Petersburg State Medical University n.a.I.P Pavlov
      • St. Petersburg, Ruská Federace, 197101
        • SHEI: First St. Petersburg State Medical University N.a.I.P Pavlov under MoH, Clinic of Bone Marrow Transplant
      • St. Petersburg, Ruská Federace, 197341
        • Federal State Budget Institute: Federal Almalov Medical Research Centre under Ministry of Healthcare
    • Komi Republic
      • Syktyvkar, Komi Republic, Ruská Federace, 167904
        • State Medical Institution Komi Republican Oncological Center
  • Spojené království
      • London, Spojené království, SW17 0QT
        • St. Georges Hospital
      • London, Spojené království, EC1A 7BE
        • St. Bartholomew's Hospital
      • London, Spojené království, NW3 2QG
        • Royal Free Hampstead
      • Nottingham, Spojené království, NG5 1PB
        • Nottingham University Hospitals (City Campus)
      • Sutton, Spojené království, SM2 5PT
        • Royal Marsden Hospital
      • Wolverhampton, Spojené království, WV10 OQP
        • The Royal Wolverhampton Hospital NHS Trust
  • Spojené státy
    • Arizona
      • Scottsdale, Arizona, Spojené státy, 85259
        • Mayo Clinic
    • California
      • Burbank, California, Spojené státy, 91505
        • Providence St. Joseph Medical Center
      • Santa Rosa, California, Spojené státy, 94503
        • St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare
      • Stanford, California, Spojené státy, 94305
        • Stanford University
    • Colorado
      • Denver, Colorado, Spojené státy, 80218
        • Colorado Blood Cancer Institute
    • Florida
      • Lecanto, Florida, Spojené státy, 34461
        • Cancer and Blood Disease Center
    • Illinois
      • Chicago, Illinois, Spojené státy, 60612
        • Rush University Medical Center
    • Indiana
      • Indianapolis, Indiana, Spojené státy, 46202
        • Indiana University Health Melvin and Bren Simon Cancer Center
    • Kansas
      • Kansas City, Kansas, Spojené státy, 66160
        • University of Kansas Cancer Center
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48109
        • The University of Michigan - Comprehensive Cancer Center
    • Minnesota
      • Rochester, Minnesota, Spojené státy, 55905
        • Mayo Clinic
    • New Jersey
      • Hackensack, New Jersey, Spojené státy, 07601
        • John Theurer Cancer Center at Hackensack University Medical Center
    • New York
      • New York, New York, Spojené státy, 10016
        • NYU Clinical Cancer Center
      • New York, New York, Spojené státy, 10021
        • Weill Cornell Medical College
    • Tennessee
      • Chattanooga, Tennessee, Spojené státy, 37404
        • Associates in Oncology and Hematology
    • Texas
      • Amarillo, Texas, Spojené státy, 79106
        • The Don & Sybil Harrington Cancer Center
      • Dallas, Texas, Spojené státy, 75246
        • Baylor Sammons Cancer Center
      • Dallas, Texas, Spojené státy, 75390-8565
        • UT Southwestern Medical Center at Dallas
      • Houston, Texas, Spojené státy, 77030
        • The University of Texas, MD Anderson Cancer Center
      • Temple, Texas, Spojené státy, 76508
        • Scott and White Memorial Hospital
    • Washington
      • Seattle, Washington, Spojené státy, 98109
        • Fred Hutchinson Cancer Research Center
    • Wisconsin
      • Milwaukee, Wisconsin, Spojené státy, 53226
        • Froedtert & Medical College of Wisconsin
  • Srbsko
      • Belgrade, Srbsko, 11000
        • Clinical Center of Serbia, Clinic of Hematology
      • Belgrade, Srbsko, 11000
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade, Srbsko, 11000
        • Military Medical Academy, Clinic of Hematology
      • Nis, Srbsko, 18 000
        • Clinical Center Nis, Clinic of Hematology
      • Novi Sad, Srbsko, 21 000
        • Clinical Center of Vojvodina, Clinic of Hematology
  • Česko
      • Brno, Česko, 625 00
        • University Hospital Brno, Department of Internal Medicine - Hematooncology
      • Hradec Kralove, Česko, 500 05
        • University Hospital Hradec Kralove
      • Olomouc, Česko, 775 20
        • University Hospital Olomouc
      • Praha 10, Česko, 100 34
        • University Hospital Kralovske Vinohrady - Prague
      • Praha 2, Česko, 128 08
        • General University Hospital Prague
  • Řecko
      • Athens, Řecko, 11528
        • Alexandra Hospital
      • Patras, Řecko, 26500
        • University General Hospital of Patras
  • Španělsko
      • Badalona, Španělsko, 08916
        • Hospital Universitario Germans Trias i Pujol
      • Barcelona, Španělsko, 08036
        • Hospital Clinic I Provincial
      • Salamanca, Španělsko, 37007
        • Hospital Universitario de Salamanca
      • San Sebastian, Španělsko, 20014
        • Hospital Donostia
      • Valencia, Španělsko, 46026
        • Hospital Universitario y Politeecnico La Fe
      • Zaragoza, Španělsko, 50009
        • Hospital Universitario Miguel Servet
  • Švédsko
      • Goteborg, Švédsko, SE-41345
        • Sahlgrenska Universitetssjukhuset
      • Stockholm, Švédsko, SE-14186
        • Karolinska Universitetsjukhuset i Huddinge
      • Stockholm, Švédsko, SE-17176
        • Karolinska Universitetssjukhuset Solna, Hematologiskt Centrum

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Symptomatic multiple myeloma

  2. Measurable disease, as defined by one or more of the following (assessed within 21 days prior to randomization):

    • Serum M-protein ≥ 0.5 g/dL
    • Urine Bence-Jones protein ≥ 200 mg/24 hours
    • For immunoglobulin A (IgA) patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL)
  3. Prior treatment with at least one, but no more than three, regimens for multiple myeloma
  4. Documented relapse or progressive disease on or after any regimen
  5. Achieved a response to at least one prior regimen
  6. Age ≥ 18 years
  7. Life expectancy ≥ 3 months
  8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  9. Adequate hepatic function, with serum alanine aminotransferase (ALT) ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 21 days prior to randomization
  10. Absolute neutrophil count ≥ 1.0 × 10^9/L within 21 days prior to randomization
  11. Hemoglobin ≥ 8 g/dL (80 g/L) within 21 days prior to randomization
  12. Platelet count ≥ 50 × 10^9/L (≥ 30 × 10^9/L if myeloma involvement in the bone marrow is > 50%) within 21 days prior to randomization
  13. Creatinine clearance (CrCl) ≥ 50 mL/minute within 21 days prior to randomization
  14. Written informed consent in accordance with federal, local, and institutional guidelines
  15. Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception
  16. Male subjects must agree to practice contraception

Exclusion Criteria:

  1. If previously treated with bortezomib (alone or in combination), progression during treatment

  2. If previously treated with a lenalidomide and dexamethasone (len/dex) combination:

    • Progression during the first 3 months of initiating treatment
    • Any progression during treatment if the len/dex combination was the subject's most recent line of therapy
  3. Discontinuation of previous lenalidomide or dexamethasone due to intolerance; subjects intolerant to bortezomib are not excluded
  4. Prior carfilzomib treatment
  5. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  6. Waldenström's macroglobulinemia or IgM myeloma
  7. Plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)
  8. Chemotherapy or investigational agent within 3 weeks prior to randomization or antibody therapy within 6 weeks prior to randomization
  9. Radiotherapy to multiple sites or immunotherapy/antibody therapy within 28 days prior to randomization; localized radiotherapy to a single site within 7 days prior to randomization
  10. Corticosteroid therapy at a dose equivalent to dexamethasone > 4 mg/day within 21 days prior to randomization
  11. Pregnant or lactating females
  12. Major surgery within 21 days prior to randomization
  13. Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization
  14. Known human immunodeficiency virus infection
  15. Active hepatitis B or C infection
  16. Myocardial infarction within 4 months prior to randomization, New York Hear Association (NYHA) Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker
  17. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization
  18. Other malignancy, including myelodysplastic syndromes (MDS), within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
  19. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization
  20. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
  21. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
  22. Ongoing graft-vs-host disease
  23. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
  24. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Lenalidomide and Dexamethasone (Rd)
Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.
Lék: Lenalidomid
25 mg perorálně ve dnech 1-21
Ostatní jména:
  • Revlimid
Lék: Dexamethasone
40 mg orally or IV on days 1, 8, 15, 22
Experimentální: Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.
Lék: Lenalidomid
25 mg perorálně ve dnech 1-21
Ostatní jména:
  • Revlimid
Lék: Dexamethasone
40 mg orally or IV on days 1, 8, 15, 22
Lék: Carfilzomib
20 mg/m², 27 mg/m² intravenously
Ostatní jména:
  • PR-171
  • Kyprolis®

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression-free Survival (PFS)
Časové okno: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). One or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).
From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Overall Survival
Časové okno: From randomization through the data cutoff date of 28 April 2017 for the final analysis of overall survival; median follow up time was 67.1 months in each treatment group.
Overall survival (OS) was defined as the duration from randomization to death due to any cause. Participants who were still alive were censored at the date when the participant was last known to be alive or the data cutoff date, whichever occurred earlier.
From randomization through the data cutoff date of 28 April 2017 for the final analysis of overall survival; median follow up time was 67.1 months in each treatment group.
Overall Response Rate
Časové okno: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Overall response rate is defined as the percentage of participants who achieved either a confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).
From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Disease Control Rate
Časové okno: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Disease control rate was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria).
From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Duration of Response
Časové okno: From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.
Duration of response (DOR) was calculated for participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.
From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.
Duration of Disease Control
Časové okno: From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.
Duration of disease control (DDC) was calculated for participants who achieved disease control. DDC was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.
From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.
Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores
Časové okno: Cycle 1 Day 1 (Baseline), Day 1 of Cycles 3, 6, 12, 18
Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life.
Cycle 1 Day 1 (Baseline), Day 1 of Cycles 3, 6, 12, 18

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Amgen

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Užitečné odkazy

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

14. července 2010

Primární dokončení (Aktuální)

16. června 2014

Dokončení studie (Aktuální)

5. prosince 2017

Termíny zápisu do studia

První předloženo

2. března 2010

První předloženo, které splnilo kritéria kontroly kvality

2. března 2010

První zveřejněno (Odhad)

4. března 2010

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

21. září 2022

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

8. září 2022

Naposledy ověřeno

1. září 2022

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • PX-171-009

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Relaps mnohočetného myelomu

Klinické studie na Lenalidomid

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Lithuania

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit